



Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Stage II or III early breast cancer at high risk of recurrence
 - a. Used for adjuvant treatment
 - b. **Kisqali only**: used in combination with an aromatase inhibitor
2. Advanced or metastatic breast cancer
 - a. **Kisqali only**: Patient has **ONE** of the following:
 - i. Used in combination with an aromatase inhibitor as initial endocrine-based therapy
 - ii. Used in combination with Faslodex (fulvestrant) as initial endocrine-based therapy or following disease progression on endocrine therapy
 - b. **Kisqali Femara Co-Pack only**: used as initial endocrine-based therapy

AND ALL of the following:

1. Hormone receptor (HR)-positive
2. Human epidermal growth factor receptor 2 (HER2)-negative
3. Prescriber agrees to treat with a luteinizing hormone-releasing hormone (LNRH) agonist if clinically indicated
4. Prescriber agrees to monitor liver function tests (LFTs), electrocardiograms (ECGs), complete blood count (CBC), and electrolytes prior to initiation of treatment and before each cycle as clinically indicated

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses



**BlueCross
BlueShield**

Federal Employee Program.

**KISQALI / KISQALI FEMARA CO-PACK
(ribociclib) / (ribociclib & letrozole)**

Patient must have **ONE** of the following:

1. Stage II or III breast cancer
 - a. **Kisqali only:** used in combination with an aromatase inhibitor
2. Advanced or metastatic breast cancer
 - a. **Kisqali only:** Patient is using in combination with **ONE** of the following:
 - i. Aromatase inhibitor
 - ii. Faslodex (fulvestrant)

AND ALL of the following:

1. **NO** disease progression or unacceptable toxicity
2. Prescriber agrees to treat with a luteinizing hormone-releasing hormone (LNRH) agonist if clinically indicated
3. Prescriber agrees to monitor liver function tests (LFTs), electrocardiograms (ECGs), complete blood count (CBC), and electrolytes before each cycle as clinically indicated

Prior - Approval *Renewal* Limits

Same as above